Objectives:
- Explain the scientific rationale supporting the investigation and the approval process for antidotes specific to NOAC.
- Compare the inclusion and exclusion criteria for the ongoing RE-VERSE-AD and ANNEXA-4 clinical trials.
- Present clinical scenarios where NOAC antidotes could be considered for a patient.
